HighGravityDataBioMarin Pharmaceutical — May 4, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-26-000006
Showing in the filing
Enzyme Therapies
“$2,725 to $2,775”
Period
FY2026
Measure
Company-defined measure
Source
Prose
All guidance in this release · 14
Total Revenues (Full-Year) for FY2026
“between $3.825 billion and $3.925 billion”
Total Revenues Growth Rate (Y/Y, at Midpoint) for FY2026
“20%”
PALYNZIQ Revenue for FY2026
“expected to increase year-over-year”
Amicus Acquisition Impact on Non-GAAP Dilute… for FY2026
“slightly dilutive”
Non-GAAP Diluted EPS Recognized in Second Ha… for H2 FY2026
“approximately two-thirds”
Total Revenues Expected in Second Half of 2026 for H2 FY2026
“more than 55%”
Non-GAAP Diluted EPS (Q2 vs Q1) for Q2 FY2026
“modestly higher than in Q1”
Total Revenues for FY2026
“$3,825 to $3,925”
Enzyme Therapies for FY2026
“$2,725 to $2,775”
VOXZOGO for FY2026
“$975 to $1,025”
Other Revenues for FY2026
“$100 to $125”
Non-GAAP Diluted EPS for FY2026
“$4.85 to $5.05”
Non-GAAP Diluted EPS - Weighted-Average Dilu… for FY2026
“approximately 200 million”
Non-GAAP Diluted EPS - combined company tax … for FY2026
“22%”
Exhibit 99.1 · the passage around this item
… earlier in the release
• The company expects approximately two-thirds of 2026 Non-GAAP Diluted EPS to be recognized in the second half of 2026, primarily due to the anticipated timing of revenue (more than 55% of 2026 Total Revenues is expected in 2H). Non-GAAP Diluted EPS in Q2 is expected to be modestly higher than in Q1. Item Provided on February 23, 2026 Updated May 4, 2026 Total Revenues $3,325 to $3,425 $3,825 to $3,925 Enzyme Therapies $2,225 to $2,275 $2,725 to $2,775 VOXZOGO $975 to $1,025 Unchanged Other Revenues (1) $100 to $125 Unchanged Non-GAAP Diluted EPS (2)(3)(4) $4.95 to $5.15 $4.85 to $5.05 (1) Other Revenues includes KUVAN, ROCTAVIAN, and royalties. (2) Refer to Non-GAAP Information beginning on page 9 of this press release for definition of Non-GAAP Diluted EPS. (3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. (4) Non-GAAP Diluted EPS guidance assumes a combined company tax rate of 22%, which is subject to change as the company completes its integration activities and purchase accounting. BioMarin will host a conference call and webcast to discuss first quarter 2026 financial results today, Monday, May 4, 2026, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 800-715-9871 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-307-1963 Replay International Dial-in Number: 609-800-9909 Conference ID: 3424435 Conference ID: 3424435 4 About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medi
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.